The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Eric Van Cutsem
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Charles S. Fuchs
Leadership - CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; Entrinsic Health
Consulting or Advisory Role - Agios; Bain Capital; Bayer; Celgene; CytomX Therapeutics; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Pfizer; Sanofi; Taiho Pharmaceutical; Unum Therapeutics
 
Lucjan Wyrwicz
Honoraria - Amgen; Roche
Consulting or Advisory Role - Halozyme; Sanofi; SERVIER
Research Funding - Bristol-Myers Squibb; Eisai; MSD
Patents, Royalties, Other Intellectual Property - Cervico
Travel, Accommodations, Expenses - Amgen; Roche; Sanofi; SERVIER
 
Keun Wook Lee
Research Funding - ALX Oncology (Inst); Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst)
 
Iveta Kudaba
No Relationships to Disclose
 
Marcelo Garrido
Research Funding - Novartis; Pfizer
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Hugo Raul Castro Salguero
No Relationships to Disclose
 
Wasat Mansoor
Speakers' Bureau - Lilly
 
Maria Ignez Freitas Melro Braghiroli
Honoraria - MSD; Roche
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca; MSD; Roche
Travel, Accommodations, Expenses - MSD
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Lilly; MSD
 
Joseph Chao
Consulting or Advisory Role - AstraZeneca (Inst); Boston Biomedical; Five Prime Therapeutics; Lilly; Merck
Speakers' Bureau - Merck
Research Funding - Merck (Inst); Novonco Therapeutics (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Uma Kher
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sukrut Shah
Employment - Merck
Stock and Other Ownership Interests - Merck
 
SoonMo Peter Kang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; MSD; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)